The development of agonists or antagonists targeting specific receptors (i.e., galr1, galr2, OTR, and npy-y1r) in the CNS may be a great opportunity to achieve a fast recovery from PPD and maternal anxiety in order to counteract the negative PPD-inducing effects on pair bonding and attachment, which may lead to psychiatric disorders during child development. The gene discussed is GALR1; the disease is Anxiety.